Open an account

Conmed

CNMD · NYSE

$47.58+$1.53 (+3.32%)TodayMarket closed ·
Prev close $46.05

About CNMD

CONMED Corp. is a medical technology company, which engages in providing devices and equipment for surgical procedures. The company is headquartered in Largo, Florida and currently employs 3,900 full-time employees. Its products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Its product lines consist of orthopedic surgery and general surgery. Orthopedic surgery consists of sports medicine instrumentation and lower extremities instrumentation and implants, small bone, large bone and specialty-powered surgical instruments as well as imaging systems for use in minimally invasive surgical procedures and service fees related to the promotion and marketing of sports medicine allograft tissue. General surgery consists of a complete line of endo-mechanical instrumentation for minimally invasive laparoscopic and gastrointestinal procedures, smoke evacuation devices, a line of cardiac monitoring products as well as electrosurgical generators and related instruments.

Employees
3,900
Headquarters
Largo, Florida
Listed
Jul 23, 1987
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
conmed.com

CNMD key statistics

Market cap
1.38B
Price-earnings ratio
24.89
Dividend yield
0.90%
Average volume
379.90K
Volume
440.17K
Open price
$47.03
High today
$48.00
Low today
$45.82
52 Week high
$53.66
52 Week low
$31.44

Conmed (CNMD) at a glance

As of Oct 20, 2026, Conmed (CNMD) shares are priced at $47.58, giving the company a market cap of 1.38B, a price-to-earnings ratio of 24.89 and a dividend yield of 0.90%.

Today the stock has traded between $45.82 and $48.00. The current price is 3.9% above the day's low and 0.9% below its high.

Volume so far is 440.17K shares, in line with the average of 379.90K shares a day.

Over the past year Conmed has ranged from $31.44 to $53.66, and now sits 73% of the way up that range.

Conmed met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q2 FY26 it reported $1.38 per share against an estimate of $1.13.

The average analyst price target is $46.51, 2.2% below the current price, from 7 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

0%of 7 analyst ratings say Buy
  • Buy0.0%
  • Hold85.7%
  • Sell14.3%
Price target · 8 analystsAvg $46.51
Low
$43.43
Now
$47.58
High
$51.45

CNMD earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 7.9% on average.

  1. Q3 FY24: reported $1.05 per share against an estimate of $1.01
  2. Q4 FY24: reported $1.34 per share against an estimate of $1.23
  3. Q1 FY25: reported $0.95 per share against an estimate of $0.8277
  4. Q2 FY25: reported $1.15 per share against an estimate of $1.15
  5. Q3 FY25: reported $1.08 per share against an estimate of $1.07
  6. Q4 FY25: reported $1.43 per share against an estimate of $1.35
  7. Q1 FY26: reported $0.89 per share against an estimate of $0.8354
  8. Q2 FY26: reported $1.38 per share against an estimate of $1.13

CNMD news

  • Press releaseBusiness Wire

    CONMED Corporation to Report Third Quarter 2026 Financial Results on October 28, 2026

  • Press releaseBusiness Wire

    CONMED Corporation to Participate in the Wells Fargo 21st Annual Healthcare Conference

  • Press releaseBusiness Wire

    CONMED Corporation Reports Second Quarter 2026 Financial Results; Updates Full Year 2026 Guidance

  • Press releaseBusiness Wire

    CONMED Corporation Announces Expanded Indication for the FDA Cleared AirSeal® Robotic Solution for Use with the Intuitive da Vinci 5 Hex Cannula

  • Press releaseBusiness Wire

    CONMED Corporation to Participate in the Society of Robotic Surgery Annual Meeting

  • Press releaseBusiness Wire

    CONMED Corporation to Report Second Quarter 2026 Financial Results on July 29, 2026

  • Press releaseBusiness Wire

    CONMED Corporation Appoints John E. Gallagher as Chief Financial Officer

  • Press releaseBusiness Wire

    CONMED Corporation Appoints Celine Martin and Jeff Mirviss to its Board of Directors

Similar companies

Companies in the same industry as Conmed

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.